id,indicator_code,spatial_dim_type,iso_code,time_dim_type,region_code,region,dim1type,year,dim1,dim2type,dim2,dim3type,dim3,data_source_dim_type,data_source_dim,value,numeric_value,low,high,comments,date,time_dimension_value,time_dimension_begin,time_dimension_end,country,indicator_name,language,title
4360,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
21562,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
56622,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
60214,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
60933,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
81135,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
100732,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
106871,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
125158,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
125699,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
132717,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
135964,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
142514,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
167126,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
177751,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
182230,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
184615,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
193431,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
206854,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
217215,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
223877,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
237072,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
245550,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
259415,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
273370,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
296784,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
312337,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
313346,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
318604,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
326882,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
341411,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
346592,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
348914,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
349447,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
363719,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
377725,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
379645,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
398109,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
419799,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
426115,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
428624,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
450455,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
453378,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
475749,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
496051,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
509006,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
535531,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
550039,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
554334,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
583869,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
585962,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
606675,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
614548,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
619855,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
634212,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
640960,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
653781,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
659288,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
661577,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
702527,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
707516,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
722980,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
725588,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
735402,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
736936,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
757465,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
766156,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
782605,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
792461,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
795834,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
802970,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
811062,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
821897,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
840547,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
845520,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
862459,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
881940,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
888880,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
892580,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
892913,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
906075,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
923068,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
937288,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
940138,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
940186,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
952278,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
952554,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
952560,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
990888,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1018260,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1022233,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1031670,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1034203,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1048425,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1048764,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1058365,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1062355,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1080892,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1085340,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1093975,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1116753,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1154607,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1157665,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1175524,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1176153,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1250299,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1265563,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1269799,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1270666,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1293385,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1299930,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1304054,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1320562,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1342965,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1348292,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1352352,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1355541,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1381603,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1410583,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1422057,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1422999,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1425867,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1431398,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1437902,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1438632,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1441538,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1452645,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1488435,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1489935,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1540296,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1542315,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1546219,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1549827,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1552147,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1559244,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1561826,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1576453,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1582144,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1602425,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1617761,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1633699,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1652051,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1655811,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1664890,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1682343,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1708086,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1713316,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1728179,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1753443,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1762460,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1791585,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1829954,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1832352,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1835198,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1849015,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1861821,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1869914,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1883421,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1892739,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1899167,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1919056,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1925731,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1932749,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1945435,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1946923,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1950760,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1960221,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1967980,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
1983052,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2003287,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2023480,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2050266,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2057616,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2073863,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2090225,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2093260,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2103438,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2116613,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2126606,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2126919,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2133527,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2156042,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2159581,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2163956,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2176464,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2180881,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2187379,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2210722,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2221667,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2230803,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2237100,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2242931,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2265684,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2280178,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2291052,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2310261,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2328638,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2332139,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2348124,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2351652,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2369160,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2369991,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2372792,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2375662,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2375906,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2380920,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2388342,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2394803,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2396069,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2405432,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2406609,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2408426,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2417738,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2419271,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2422805,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2462950,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2464970,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2473708,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2482506,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2502643,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2509716,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2513810,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2525040,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2528684,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2535356,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2536681,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2559787,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2560151,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2565573,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2581520,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2584824,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2608272,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2608766,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2611982,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2616801,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2632983,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2641177,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2667457,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2671285,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2685098,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2694563,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2696848,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2699583,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2720618,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2735321,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2735843,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2752071,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2759420,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2761597,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2781188,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2783396,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2788903,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2791644,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2791822,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2792482,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2795147,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2809280,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2835279,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2848025,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2851764,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2860542,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2867890,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2868796,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2874764,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2897864,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2898223,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2913670,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2944913,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2971958,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2973634,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
2994309,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3011320,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3015814,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3016259,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3025339,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3036158,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3054682,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3066061,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3093246,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3113036,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3115390,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3118813,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3154212,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3158435,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3160992,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3180029,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3189395,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3205505,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3213877,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3217039,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3222395,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3242884,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3244352,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3246222,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3249142,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3285523,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3286674,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3290323,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3292817,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3322483,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3347306,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3374306,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3380039,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3395386,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3409858,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3430041,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3436832,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3440396,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3449705,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3457630,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3465084,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3489304,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3489696,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3494003,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3497298,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3504560,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3509835,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3520733,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3525554,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3545625,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3553439,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3559321,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3560193,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3561303,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3567953,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3573657,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3610488,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3620033,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3641920,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3645336,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3655512,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3665414,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3675467,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3684958,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3702441,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3704244,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3707012,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3716273,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3752493,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3753478,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3757216,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3764406,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3798488,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3803628,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3840903,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3847456,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3852753,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3861068,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3862081,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3864397,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3879724,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3880941,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3888986,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3897630,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3929287,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3934895,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3939696,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3950650,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3952167,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3982632,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3987370,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3987426,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3989392,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3994232,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
3996135,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4034615,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4036458,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4041829,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4045910,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4046353,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4050440,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4051074,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4065202,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4066551,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4067866,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4083433,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4093238,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4099126,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4102943,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4109070,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4130051,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4135120,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4146201,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4147231,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4163523,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4169387,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4173052,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4183741,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4201289,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4222070,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4233453,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4239083,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4239272,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4242718,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4249815,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4261855,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4272343,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4273116,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4278092,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4278477,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4297831,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4317065,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4326839,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4330054,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4335774,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4356363,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4370160,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4370443,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4384201,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4395747,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4398388,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4405683,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4407909,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4433881,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4450086,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4471048,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4481791,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4509704,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4532523,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4541600,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4552970,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4565980,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4572904,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4575512,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4577659,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4588059,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4594261,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4601728,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4611533,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4612846,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4613610,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4617573,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4618336,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4619963,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4626264,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4635734,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4641142,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4647978,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4660118,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4660133,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4672688,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4696329,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4711530,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4714335,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4717679,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4725234,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4725311,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4725950,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4729255,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4743109,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4760634,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4781022,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4789731,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4792416,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4795179,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4804657,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4807167,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4809474,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4824099,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4824381,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4840371,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4843790,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4853856,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4857887,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4862498,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4874514,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4884701,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4893082,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4903863,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4916478,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4927116,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4932498,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4957085,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4980429,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4983879,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4984778,SCSUD_MEDREG,COUNTRY,KEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kenya,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4992424,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
4993494,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5020933,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5031673,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5036243,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5038104,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5049003,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5049458,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5066217,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5069004,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5069898,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5070557,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5071431,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5072649,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5077707,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5078415,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5082524,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5087896,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5090100,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5110074,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5134169,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5138304,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5145007,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5168484,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5170847,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5177309,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5201878,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5205112,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5231169,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5239810,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5241400,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5256567,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5269048,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5272129,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5274636,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5290383,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5292139,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5297606,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5304348,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5309483,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5309879,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5311794,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5319660,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5322452,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5333786,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5336968,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5337699,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5342847,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5354146,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5354980,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5371027,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5374448,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5375742,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5376925,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5381205,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5381754,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5385008,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5405442,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5407148,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5408417,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5410562,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5438970,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5440838,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5457800,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5470970,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5472922,SCSUD_MEDREG,COUNTRY,BGD,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bangladesh,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5478334,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5483988,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5484207,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5497366,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5516309,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5516485,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5531503,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5555122,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5568252,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5582145,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5589679,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5603120,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5615610,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5616153,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5632948,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5639627,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5641091,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5653529,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5656563,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5666331,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5671631,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5673435,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5681876,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5685963,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5690315,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5691388,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5694006,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5707276,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5719788,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5727715,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5750405,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5751167,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5758697,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5767913,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5793575,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5803684,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5808590,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5819663,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5826946,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5828436,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5831828,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5840815,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5846496,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5850042,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5855991,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5871551,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5876849,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5901333,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5954280,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5969452,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5969486,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5992244,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6012832,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6015314,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6032129,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6036384,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6048779,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6049221,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6050676,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6051565,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6056163,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6073008,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6111277,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6155967,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6158192,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6165789,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6168516,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6175282,SCSUD_MEDREG,COUNTRY,GHA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ghana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6175515,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6189594,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6190470,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6193553,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6196551,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6205642,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6210909,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6226005,SCSUD_MEDREG,COUNTRY,LVA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Latvia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6234046,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6240180,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6241032,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6245101,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6256321,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6259820,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6315484,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6319838,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6325257,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6328425,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6331993,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6341181,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6342803,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6346920,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6347859,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6373523,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6390045,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6391537,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6405874,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6420002,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6420911,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6430050,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6443036,SCSUD_MEDREG,COUNTRY,TUR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Türkiye,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6443948,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6446666,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6447787,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6457112,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6469190,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6475977,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6477624,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6488388,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6492158,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6509605,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6509955,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6514697,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6535002,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6536565,SCSUD_MEDREG,COUNTRY,SRB,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Serbia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6560322,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6573755,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6612897,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6622981,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6624552,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6653385,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6655946,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6657868,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6664214,SCSUD_MEDREG,COUNTRY,OMN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Oman,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6672885,SCSUD_MEDREG,COUNTRY,GRC,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Greece,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6685313,SCSUD_MEDREG,COUNTRY,KHM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cambodia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6728570,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6744730,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6750823,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6753222,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6788029,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6790046,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6827538,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6836827,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6844548,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6845089,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6856345,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6872775,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6886568,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6896514,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6907727,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6908365,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6925273,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6928279,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6954127,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6954752,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6957319,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6962867,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6964383,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6974070,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6987134,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
6999337,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7019371,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7033713,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7034877,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7041806,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7058746,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7059780,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7066027,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7066367,SCSUD_MEDREG,COUNTRY,PRT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Portugal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7074489,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7080212,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7081019,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7082803,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7091144,SCSUD_MEDREG,COUNTRY,AGO,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Angola,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7096710,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7100640,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7108860,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7123714,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7139851,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7152372,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7153335,SCSUD_MEDREG,COUNTRY,MDA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Moldova,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7154356,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7155315,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7164587,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7175398,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7180759,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7210587,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7232963,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7233241,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7234787,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7239015,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7239210,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7252078,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7252866,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7264012,SCSUD_MEDREG,COUNTRY,PNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Papua New Guinea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7289986,SCSUD_MEDREG,COUNTRY,DEU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Germany,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7291678,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7296940,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7305091,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7309060,SCSUD_MEDREG,COUNTRY,EST,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Estonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7326780,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7327664,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7329170,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7339007,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7347273,SCSUD_MEDREG,COUNTRY,LBR,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Liberia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7348756,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7356922,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7358459,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7360039,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7361339,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7376256,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7378655,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7397641,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7406821,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7414156,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7442363,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7444901,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7444932,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7451662,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7460233,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7472594,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7517698,SCSUD_MEDREG,COUNTRY,MNG,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mongolia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7532902,SCSUD_MEDREG,COUNTRY,SVN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7538880,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7553014,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7554541,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7554785,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7556345,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7606076,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7606762,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7615589,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7621333,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7624673,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7630981,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7632607,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7632997,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7648477,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7648534,SCSUD_MEDREG,COUNTRY,JAM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jamaica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7655418,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7664625,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7665288,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7672021,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7692514,SCSUD_MEDREG,COUNTRY,MLT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malta,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7697996,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7711995,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7713351,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7716569,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7734103,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7744697,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7776510,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7783459,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7784490,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7784662,SCSUD_MEDREG,COUNTRY,RUS,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Russian Federation,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7794759,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7795282,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7797197,SCSUD_MEDREG,COUNTRY,MLI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mali,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7814820,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7843617,SCSUD_MEDREG,COUNTRY,BFA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burkina Faso,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7844732,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7855119,SCSUD_MEDREG,COUNTRY,BRB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Barbados,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7866231,SCSUD_MEDREG,COUNTRY,TKM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Turkmenistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7869788,SCSUD_MEDREG,COUNTRY,KGZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kyrgyzstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7870560,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7903471,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7938156,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7941556,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7950035,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7965055,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7966481,SCSUD_MEDREG,COUNTRY,DNK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Denmark,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7973578,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7980722,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7985213,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7987867,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7990568,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7990928,SCSUD_MEDREG,COUNTRY,SSD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
7995242,SCSUD_MEDREG,COUNTRY,CZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Czechia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8006016,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8014338,SCSUD_MEDREG,COUNTRY,FSM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Micronesia (Federated States of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8030588,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8033149,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8041964,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8054884,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8067010,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8071590,SCSUD_MEDREG,COUNTRY,BRA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Brazil,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8076082,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8104657,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8112152,SCSUD_MEDREG,COUNTRY,SEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Senegal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8118640,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8133919,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8141644,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8164344,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8185808,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8187253,SCSUD_MEDREG,COUNTRY,FRA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,France,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8208892,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8223488,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8226535,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8226665,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8231506,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8231832,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8235764,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8237299,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8257497,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8289371,SCSUD_MEDREG,COUNTRY,COL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Colombia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8301818,SCSUD_MEDREG,COUNTRY,BDI,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Burundi,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8307685,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8324935,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8337224,SCSUD_MEDREG,COUNTRY,SDN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sudan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8340884,SCSUD_MEDREG,COUNTRY,CAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Central African Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8344360,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8356804,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8360720,SCSUD_MEDREG,COUNTRY,ATG,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Antigua and Barbuda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8395613,SCSUD_MEDREG,COUNTRY,TUN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tunisia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8404824,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8437933,SCSUD_MEDREG,COUNTRY,VUT,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Vanuatu,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8459825,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8461045,SCSUD_MEDREG,COUNTRY,SAU,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saudi Arabia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8473238,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8479202,SCSUD_MEDREG,COUNTRY,SVK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Slovakia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8499990,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8503140,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8527321,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8586975,SCSUD_MEDREG,COUNTRY,BHR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bahrain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8596505,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8609233,SCSUD_MEDREG,COUNTRY,CRI,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Costa Rica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8612976,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8615909,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8616601,SCSUD_MEDREG,COUNTRY,SLE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sierra Leone,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8633100,SCSUD_MEDREG,COUNTRY,SWE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sweden,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8645957,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8656289,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8656689,SCSUD_MEDREG,COUNTRY,COD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Democratic Republic of the Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8658004,SCSUD_MEDREG,COUNTRY,MCO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Monaco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8661629,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8673021,SCSUD_MEDREG,COUNTRY,COG,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Congo,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8676914,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8696832,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8726342,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8731816,SCSUD_MEDREG,COUNTRY,FIN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Finland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8764121,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8769869,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8775383,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8785511,SCSUD_MEDREG,COUNTRY,KNA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Kitts and Nevis,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8799222,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8815331,SCSUD_MEDREG,COUNTRY,ISR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Israel,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8837176,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8840860,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8843741,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8858056,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8869886,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8871778,SCSUD_MEDREG,COUNTRY,TJK,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tajikistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8887364,SCSUD_MEDREG,COUNTRY,ESP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Spain,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8894741,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8901803,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8902558,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8904588,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8919346,SCSUD_MEDREG,COUNTRY,QAT,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Qatar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8921200,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8929690,SCSUD_MEDREG,COUNTRY,ARM,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Armenia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8968742,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8989711,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
8989941,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9011244,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9018275,SCSUD_MEDREG,COUNTRY,MOZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mozambique,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9021121,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9022950,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9037549,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9053408,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9054937,SCSUD_MEDREG,COUNTRY,BEL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belgium,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9057743,SCSUD_MEDREG,COUNTRY,SWZ,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Eswatini,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9063657,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9069845,SCSUD_MEDREG,COUNTRY,THA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Thailand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9076602,SCSUD_MEDREG,COUNTRY,PRY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Paraguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9089698,SCSUD_MEDREG,COUNTRY,LKA,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Sri Lanka,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9090699,SCSUD_MEDREG,COUNTRY,PHL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Philippines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9108575,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9114936,SCSUD_MEDREG,COUNTRY,CUB,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cuba,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9117597,SCSUD_MEDREG,COUNTRY,VNM,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Viet Nam,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9121516,SCSUD_MEDREG,COUNTRY,PAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Panama,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9132672,SCSUD_MEDREG,COUNTRY,DMA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominica,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9140076,SCSUD_MEDREG,COUNTRY,VCT,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Vincent and the Grenadines,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9155965,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9175740,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9184359,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9185530,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9189211,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9196209,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9202769,SCSUD_MEDREG,COUNTRY,BLZ,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belize,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9207108,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9207320,SCSUD_MEDREG,COUNTRY,MKD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,North Macedonia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9223488,SCSUD_MEDREG,COUNTRY,DOM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Dominican Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9232112,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9264754,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9270321,SCSUD_MEDREG,COUNTRY,UGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uganda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9271297,SCSUD_MEDREG,COUNTRY,MYS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Malaysia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9277068,SCSUD_MEDREG,COUNTRY,TCD,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chad,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9309693,SCSUD_MEDREG,COUNTRY,MMR,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Myanmar,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9318732,SCSUD_MEDREG,COUNTRY,ETH,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ethiopia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9341381,SCSUD_MEDREG,COUNTRY,URY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Uruguay,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9347458,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9350014,SCSUD_MEDREG,COUNTRY,AFG,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Afghanistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9375241,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9388201,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9402868,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9440143,SCSUD_MEDREG,COUNTRY,BTN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bhutan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9442439,SCSUD_MEDREG,COUNTRY,JOR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Jordan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9464160,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9464612,SCSUD_MEDREG,COUNTRY,BLR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Belarus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9469098,SCSUD_MEDREG,COUNTRY,ZMB,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zambia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9472808,SCSUD_MEDREG,COUNTRY,NPL,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nepal,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9473615,SCSUD_MEDREG,COUNTRY,MEX,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Mexico,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9474543,SCSUD_MEDREG,COUNTRY,KAZ,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Kazakhstan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9474965,SCSUD_MEDREG,COUNTRY,GTM,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guatemala,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9484416,SCSUD_MEDREG,COUNTRY,LTU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Lithuania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9484445,SCSUD_MEDREG,COUNTRY,IND,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,India,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9485160,SCSUD_MEDREG,COUNTRY,GRD,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Grenada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9486357,SCSUD_MEDREG,COUNTRY,CHL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Chile,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9486896,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9495838,SCSUD_MEDREG,COUNTRY,JPN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Japan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9500189,SCSUD_MEDREG,COUNTRY,NIC,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nicaragua,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9517069,SCSUD_MEDREG,COUNTRY,NLD,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Netherlands (Kingdom of the),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9518758,SCSUD_MEDREG,COUNTRY,NGA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Nigeria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9525491,SCSUD_MEDREG,COUNTRY,IRQ,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iraq,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9528689,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9535575,SCSUD_MEDREG,COUNTRY,POL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Poland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9541710,SCSUD_MEDREG,COUNTRY,AZE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Azerbaijan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9546628,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9557999,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9563998,SCSUD_MEDREG,COUNTRY,AUT,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Austria,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9568207,SCSUD_MEDREG,COUNTRY,UKR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ukraine,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9602335,SCSUD_MEDREG,COUNTRY,SYC,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Seychelles,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9611765,SCSUD_MEDREG,COUNTRY,IRN,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iran (Islamic Republic of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9629433,SCSUD_MEDREG,COUNTRY,SMR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,San Marino,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9645107,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9651763,SCSUD_MEDREG,COUNTRY,CYP,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cyprus,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9658952,SCSUD_MEDREG,COUNTRY,NZL,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,New Zealand,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9673442,SCSUD_MEDREG,COUNTRY,COK,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cook Islands,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9683252,SCSUD_MEDREG,COUNTRY,LCA,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Saint Lucia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9688273,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9692995,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9700218,SCSUD_MEDREG,COUNTRY,ZWE,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Zimbabwe,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9700866,SCSUD_MEDREG,COUNTRY,ZAF,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,South Africa,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9701777,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9707131,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9714627,SCSUD_MEDREG,COUNTRY,ROU,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Romania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9719202,SCSUD_MEDREG,COUNTRY,GUY,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Guyana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9719563,SCSUD_MEDREG,COUNTRY,KOR,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Republic of Korea,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9720743,SCSUD_MEDREG,COUNTRY,SGP,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Singapore,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9731287,SCSUD_MEDREG,COUNTRY,CPV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cabo Verde,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9754538,SCSUD_MEDREG,COUNTRY,CIV,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Cote d'Ivoire,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9759453,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9780113,SCSUD_MEDREG,COUNTRY,SUR,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Suriname,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9782651,SCSUD_MEDREG,COUNTRY,CAN,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Canada,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9805246,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9817315,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9821068,SCSUD_MEDREG,COUNTRY,PER,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Peru,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9828609,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9880384,SCSUD_MEDREG,COUNTRY,ECU,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ecuador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9901159,SCSUD_MEDREG,COUNTRY,AND,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Andorra,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9910456,SCSUD_MEDREG,COUNTRY,BOL,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Bolivia (Plurinational State of),"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9911354,SCSUD_MEDREG,COUNTRY,CHE,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Switzerland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9937231,SCSUD_MEDREG,COUNTRY,MAR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Morocco,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9949262,SCSUD_MEDREG,COUNTRY,SYR,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Syrian Arab Republic,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9953141,SCSUD_MEDREG,COUNTRY,NOR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Norway,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9976709,SCSUD_MEDREG,COUNTRY,SLV,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,El Salvador,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
9994773,SCSUD_MEDREG,COUNTRY,BWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Botswana,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10002269,SCSUD_MEDREG,COUNTRY,EGY,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_acamprosate,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Egypt,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10015905,SCSUD_MEDREG,COUNTRY,IRL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10016234,SCSUD_MEDREG,COUNTRY,HRV,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Croatia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10017223,SCSUD_MEDREG,COUNTRY,GBR,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Kingdom of Great Britain and Northern Ireland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10018789,SCSUD_MEDREG,COUNTRY,LUX,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Luxembourg,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10021914,SCSUD_MEDREG,COUNTRY,HUN,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Hungary,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10038205,SCSUD_MEDREG,COUNTRY,TZA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_clonidine_lofexidine,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,United Republic of Tanzania,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10038876,SCSUD_MEDREG,COUNTRY,SOM,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Somalia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10055526,SCSUD_MEDREG,COUNTRY,RWA,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Rwanda,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10056325,SCSUD_MEDREG,COUNTRY,GEO,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Georgia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10064022,SCSUD_MEDREG,COUNTRY,PAK,YEAR,EMR,Eastern Mediterranean,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Pakistan,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10066918,SCSUD_MEDREG,COUNTRY,ISL,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Iceland,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10115525,SCSUD_MEDREG,COUNTRY,AUS,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_methadone,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Australia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10116995,SCSUD_MEDREG,COUNTRY,TON,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_naltrexone,NA,NA,NA,NA,NA,NA,0,0,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Tonga,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10123910,SCSUD_MEDREG,COUNTRY,CHN,YEAR,WPR,Western Pacific,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_disulfiram,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,China,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10125520,SCSUD_MEDREG,COUNTRY,HND,YEAR,AMR,Americas,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Honduras,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
10133150,SCSUD_MEDREG,COUNTRY,IDN,YEAR,SEAR,South-East Asia,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Indonesia,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
556503,SCSUD_MEDREG,COUNTRY,ITA,YEAR,EUR,Europe,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_regincountry_opiod_agonists,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Italy,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
5782401,SCSUD_MEDREG,COUNTRY,BEN,YEAR,AFR,Africa,SCSUDSURVEYQUESTIONS,2023,SCSUDSURVEYQUESTIONS_SCSUD43_01_registered_in_country_benzodiazepines,NA,NA,NA,NA,NA,NA,1,1,NA,NA,NA,2024-09-03T10:09:22.71+02:00,2023,2023-01-01T00:00:00+01:00,2023-12-31T00:00:00+01:00,Benin,"Substance use disorders service coverage, medicine registered in the country",EN,Service coverage for substance use disorders survey
